Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management
Launched by UNIVERSITY OF BRAWIJAYA · Jun 16, 2022
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two types of nerve block procedures—called the superior hypogastric plexus block and the ganglion impar block—to see how well they relieve pelvic and perineal pain in women with cervical or endometrial cancer. These nerve blocks are treatments that aim to reduce severe cancer pain in the lower belly and pelvic area by targeting specific nerves, especially for patients whose pain has not improved with standard pain medications.
Women aged 18 to 74 who have strong cancer pain (rated above 4 on a pain scale) that hasn’t gotten better after at least two weeks of medicine, or who are experiencing side effects from those medications, may be able to join. Before joining, a pain specialist will confirm the pain location. Participants will need to agree to the study and meet other health requirements, like not having blood clotting problems or infections in the treatment area. If they join, patients can expect to receive one of the nerve block procedures and will be closely monitored for safety and pain relief. This study is currently recruiting participants and aims to find better ways to manage difficult cancer pain with fewer side effects from medications.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Unbearable cancer pain that is resistant to WHO (World Health Organization) pain ladder at least 2 weeks medication
- • The patient is tired of taking medication orally or complications of current medication (respiratory depression, nausea, vomiting, opioid-induced constipation, gastrointestinal disturbances)
- • Patients with pelvic floor pain diagnosed by a (Fellow of Interventional Pain Practice) FIPP-certified pain specialist
- • Patients with pain in the perineum diagnosed by a FIPP-certified pain specialist
- • Numerical Rating Scale \>4
- • \>18 years old
- • Able and willing to sign an informed consent
- Exclusion Criteria:
- • Refuse to be included in the research
- • Blood clotting disorders (including taking anticoagulant drugs)
- • Local infection in the area of action
- • Loss to follow up
- Drop-out Criteria:
- • Loss to follow up
- • Intervention complications occur
- • Failed intervention
About University Of Brawijaya
The University of Brawijaya, a distinguished institution located in Indonesia, is committed to advancing medical research and public health through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive academic resources and expertise to conduct rigorous studies aimed at improving healthcare outcomes. The institution fosters a dynamic research environment, encouraging the development of novel therapies and interventions that address pressing health challenges. Through its commitment to ethical research practices and community engagement, the University of Brawijaya plays a pivotal role in contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malang, East Java, Indonesia
Patients applied
Trial Officials
Ristiawan M Laksono
Principal Investigator
Brawijaya University
Andika B Effendi
Study Director
Brawijaya University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials